E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Myocardial Injury after Noncardiac Surgery |
|
E.1.1.1 | Medical condition in easily understood language |
Myocardial Injury after Noncardiac Surgery |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028601 |
E.1.2 | Term | Myocardial ischemia |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effect of perioperative administration of ivabradine in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. Primary Objectives: To determine the effect of perioperative administration of ivabradine in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. The primary outcome is myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery
|
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives: To determine the impact of ivabradine on the following outcomes at 30 days after surgery: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; peak troponin concentration; area under the curve troponin; days alive and at home; stroke; all-cause mortality; health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria Patients are eligible for the study if they fulfill the following criteria for inclusion: 1. Undergoing noncardiac surgery; 2. ≥45 years of age; 3. Expected to require at least an overnight hospital stay after surgery; 4. Written informed consent to participate in the PREVENT-MINS Trial provided, AND 5. Fulfill ≥1 of the following 5 criteria (A-E): A. Current or prior history of coronary artery disease as defined by any one of the following 7 criteria: i. History of angina; ii. History of acute coronary syndrome; iii. History of a segmental cardiac wall motion abnormality on echocardiography or a segmental fixed defect on radionuclide imaging; iv. History of a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test demonstrating cardiac ischaemia; v. History of a coronary angiographic or CT coronary angiographic evidence of atherosclerotic stenosis ≥50% of the diameter of any coronary artery; vi. ECG with pathological Q waves in at least two contiguous leads; OR vii. Previous coronary artery revascularization, (i.e. percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]); B. Peripheral arterial disease as defined by a physician diagnosis of a current, or prior history of any of the following 4 criteria: i. Intermittent claudication; ii. Vascular surgery OR percutaneous transluminal angioplasty (PTA) for atherosclerotic disease; iii. An ankle/brachial systolic blood pressure ratio <0.90 in either leg at rest; OR iv. Angiographic, CT angiographic or doppler findings demonstrating >70% stenosis in a noncardiac artery; C. History of stroke as defined by any one of the following 2 criteria i. A physician diagnosis of stroke; OR ii. CT or MRI evidence of a prior stroke; D. Undergoing major vascular surgery defined as all vascular surgeries (including any above foot amputation) with the exception of arteriovenous shunt, vein stripping procedures (varicose vein surgery), carotid endarterectomies, endovascular abdominal aortic aneurysm repair (EVAR); OR E. Any 3 of 9 risk criteria: i. Undergoing major surgery defined as: intraperitoneal, intrathoracic, retroperitoneal, or major orthopedic; ii. History of congestive heart failure defined as a physician diagnosis of a current or prior episode of congestive heart failure OR prior radiographic evidence of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema; iii. History of a transient ischaemic attack; iv. Diabetes diagnosis and currently taking hypoglycemic agent; v. Age ≥70 years; vi. History of hypertension; vii. Serum creatinine >175 μmol/L (>2.0 mg/dl) based on the most recent values before randomisation; viii. History of smoking within 2 years of surgery; and ix. Undergoing emergent/urgent surgery, defined as surgery that a surgeon schedules to go to the operating room within 48 hours from an acute presentation to the hospital. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria 1. Conduction abnormalities: A. Non-sinus rhythm on ECG; B. Sinoatrial or AV (2nd and 3d degree) blocks; C. Sick sinus syndrome; D. Long QT syndrome; E. Pacemaker dependent; 2. Transplanted heart (or on waiting list); 3. Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil; 4. Resting heart rate <65 beats per minute on the day of surgery; 5. Systolic blood pressure <90 mmHg on the day of surgery; 6. Acute decompensated heart failure, cardiogenic shock, acute myocarditis; 7. Acute coronary syndrome within 2 months before surgery; 8. Stroke or transient cerebral ischaemia within 1 month before surgery; 9. Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min); 10. Inability to tolerate oral intake; 11. Recent use of ivabradine (<1 month); 12. Known allergy or hypersensitivity to ivabradine; 13. Low-risk surgical procedure based on individual physician's judgment 14. Investigator considers the patient unreliable regarding requirement for study compliance; 15. Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding; 16. Previously enrolled in the PREVENT-MINS trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evidence of a dynamic troponin elevation defined as follows: 1. a non-high-sensitivity troponin T ≥30 ng/L with an at least 15 ng/L change; 2. a high-sensitivity troponin T (hsTnT) level ≥20 with an absolute change of at least 5 ng/L; 3. an Abbott high-sensitivity troponin I (hsTnI) level ≥60 ng/L and a change of ≥50% of the 99th percentile upper reference limit; 4. a Siemens hsTnI level ≥75 ng/L and a change of ≥50% of the 99th percentile upper reference limit; 5. for any other hsTnI or non-hsTnI as any value above the 99th percentile upper reference limit for each specific troponin I assay and a change of ≥50% of the 99th percentile upper reference limit. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Before surgery, at postoperative day 1, 2, 3 or until hospital discharge, if hospital discharge occurs sooner than 3 days after surgery, and at Day 30 on-site follow-up visit. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At Day 30 on-site and Year 1 telephone follow-up visits. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 25 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 30 |